leisure time -WSS

leisure time

author：explore 2025-08-23 10:40:29 - browse：594

Allergan, Dom Smith/STAT

It wasn’t supposed to work out this way for Brent Saunders.

Four years ago, Saunders was the whiz kid of the pharmaceutical set. At 44, he had created a large pharmaceutical firm, then called Actavis, almost by force of will after engineering more than $100 billion in deals in a two-year span. Then he had swooped in to rescue Botox maker Allergan from the nefarious claws of Valeant Pharmaceuticals, an asset-stripping drug company loved by many on Wall Street but no one with a conscience.

As CEO, he paired his dealmaking with a boyish charm and a willingness to take on big issues that made him seem like a potential spokesman for the whole industry.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： Cytokinetics CEO stresses company can launch heart drug on its own

explore

WSS

FDA panel to weigh safety of artificial wombs for preterm births

Readers respond to H5N1 and livestock movements, and more

Readers respond to H5N1 and livestock movements, and more

How the messy conversation about Dolly changed bioethics

Transgender sports debate: Physicians say bans are health issue

Second House panel advances two

leisure time

leisure time

Wikipedia

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Transgender sports debate: Physicians say bans are health issue

Guidelines to prevent youth baseball injuries need more muscle

Case highlights the risks of experimental stem cell therapy

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

How the messy conversation about Dolly changed bioethics

BioMarin wins approval for gene therapy to treat hemophilia A

Glen Campbell's doctor discusses his public struggle with Alzheimer's

Affirmative action in medical school literally saved lives

Venture capitalist Bob Kocher on the state of digital health

hotspot

Second House panel advances two

HIV vaccine remains elusive. Immunologists keep trying new ideas

How the messy conversation about Dolly changed bioethics

Solving academic medical centers' existential crisis

FDA panel to weigh safety of artificial wombs for preterm births

PBMs drew scrutiny in House hearing — and so did pharma

focus

knowledge

explore

focus